Issue 12/2015
Content (12 Articles)
Acknowledgement to Referees
Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children
Frederique Rodieux, Melanie Wilbaux, Johannes N. van den Anker, Marc Pfister
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions
Timothy Eley, Tushar Garimella, Wenying Li, Richard J. Bertz
Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review
Hazem Elewa, Eman El-Mekaty, Ahmed El-Bardissy, Mary H. H. Ensom, Kyle John Wilby
Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Jessica K. Roberts, Chris Stockmann, Robert M. Ward, Joanna Beachy, Mariana C. Baserga, Michael G. Spigarelli, Catherine M. T. Sherwin
A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child–Pugh Classification
Julie Steelandt, Elodie Jean-Bart, Sylvain Goutelle, Michel Tod
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort
Frederik Vandenberghe, Monia Guidi, Eva Choong, Armin von Gunten, Philippe Conus, Chantal Csajka, Chin B. Eap
Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design
Stéphanie Leroux, Mark A. Turner, Chantal Barin-Le Guellec, Helen Hill, Johannes N. van den Anker, Gregory L. Kearns, Evelyne Jacqz-Aigrain, Wei Zhao
Comment on Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design
Joseph F. Standing, Brian J. Anderson, Nicholas H.G. Holford, Irja Lutsar, Tuuli Metsvaht
Author’s Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design
Wei Zhao, Evelyne Jacqz-Aigrain
Comment on: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
Nuggehally R. Srinivas